Article info

Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study

Authors

  • Joel Lexchin School of Health Policy and Management, York University, Toronto, Ontario, CanadaUniversity Health NetworkDepartment of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Joel Lexchin; jlexchin{at}yorku.ca
View Full Text

Citation

Lexchin J
Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study

Publication history

  • Received October 19, 2013
  • Revised January 26, 2014
  • Accepted January 27, 2014
  • First published February 18, 2014.
Online issue publication 
February 18, 2014
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.